Device Trial Radar · NCT03417297
A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Apr 24, 2018
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- University of North Carolina, Chapel HillAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Focused Ultrasound Foundation
- First posted
- Jan 31, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and feasibility of unilateral focused ultrasound thalamotomy in adults with focal onset epilepsy whose medicines are not working well. The ExAblate (ExAblate) transcranial system is the name of the device that will be used to create and send ultrasound waves through the scalp and skull precisely to a small structure located in the center of the brain. This structure is known as the "Anterior Nucleus", and is an important region in the brain that may cause seizures. Safety will be measured by recording and analyzing the frequency of side effects throughout participation. Feasibility will be measured by the ability to create a lesion in the anterior nucleus.
Conditions
- Partial Seizures With Secondary Generalization
- Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused UltrasoundDevice
Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Successful Lesion CreationTime frame: during the surgical procedure
- Number of Participants with Adverse EventsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of North Carolina-Chapel Hill
Chapel Hill, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.